Stephens lowers Simulations Plus stock price target to $20 on macro headwinds

Published 15/07/2025, 12:44
Stephens lowers Simulations Plus stock price target to $20 on macro headwinds

Investing.com - Stephens lowered its price target on Simulations Plus (NASDAQ:SLP) to $20.00 from $28.00 on Tuesday, while maintaining an Overweight rating on the stock. The company’s shares, currently trading at $17.47, have declined nearly 37% year-to-date and are hovering near their 52-week low of $16.72. According to InvestingPro data, the stock’s RSI suggests it’s in oversold territory.

The firm’s decision follows Simulations Plus reporting quarterly financial results that were slightly better than the negative preliminary results announced in mid-June. Despite the modest improvement, the company faces multiple macroeconomic challenges affecting its business performance. Nevertheless, InvestingPro analysis shows the company maintains strong financial health with a current ratio of 4.37 and operates with moderate debt levels.

Simulations Plus maintained its revenue guidance but slightly lowered its adjusted EBITDA outlook, which Stephens noted was below their previous model. The company cited several factors impacting its second-half performance, including client mergers and a contract cancellation resulting from a negative data readout that halted two programs.

The firm observed that demand for Simulations Plus services has weakened, though clients continue to spend on software. Client headcount growth, previously a positive factor, is no longer providing momentum for the business.

Stephens indicated that the fourth-quarter outlook likely represents conservatism rather than deteriorating fundamentals, with management expressing confidence in setting expectations for growth in fiscal year 2026.

In other recent news, Simulations Plus reported fiscal third-quarter 2025 revenue of $20.4 million, marking a 10% year-over-year increase but falling short of the $21.84 million consensus estimate. The company posted adjusted earnings per share of $0.45, significantly surpassing analyst projections of $0.25. Despite a net loss of $67.3 million due to a one-time non-cash impairment charge, adjusted EBITDA reached $7.4 million, a 37% increase from the previous year. Simulations Plus maintained its fiscal 2025 revenue guidance, projecting growth between 9-14%, and provided adjusted EPS guidance of $0.93-$1.06. Meanwhile, KeyBanc downgraded the company from Overweight to Sector Weight, citing challenges in the biopharma market and customer concentration issues. In contrast, BTIG maintained a Buy rating with a $25.00 price target, acknowledging industry headwinds but highlighting positive long-term prospects. Additionally, Simulations Plus invested $1 million in Nurocor, a clinical trial technology firm, to support innovation in the pharmaceutical industry. This strategic move aligns with the company’s broader goal of expanding its market reach and complementing its organic growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.